Drug intelligence / Profile preview

Ruitongli

Development stage: Phase 2
Lead developer: Dong-E-E-Jiao
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

**Ruitongli** is a recombinant human tissue-type plasminogen activator derivative (r-PA), a thrombolytic agent developed by Dong-E-E-Jiao and manufactured by Angde Biotech. It is approved in China for the treatment of **myocardial infarction** (since 2007) and **acute ischemic stroke** (since 2024), functioning by stimulating plasminogen to promote fibrinolysis and dissolve blood clots in acute thrombotic conditions. Administered via intravenous injection, it is being explored for additional indications like pulmonary embolism (Phase 3) and acute deep vein thrombosis.

Brand names: Ruitongli
Other names: r-PA

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on Ruitongli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ruitongli.

Explore the full profile